Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
IPO Year:
Exchange: NYSE
Website: stryker.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $405.00 | Outperform | Wolfe Research |
| 5/30/2024 | $372.00 | Neutral | Goldman |
| 5/22/2024 | $392.00 | Hold → Buy | Needham |
| 1/31/2024 | $315.00 → $360.00 | Hold → Buy | Canaccord Genuity |
| 10/20/2023 | $345.00 | Buy | ROTH MKM |
| 9/5/2023 | $310.00 → $315.00 | Neutral → Buy | BofA Securities |
| 3/29/2023 | $287.00 | Neutral | UBS |
| 1/25/2023 | Sector Weight | KeyBanc Capital Markets | |
| 1/9/2023 | $240.00 → $284.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 11/1/2022 | $225.00 → $220.00 | Buy → Hold | Canaccord Genuity |
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billionOrganic net sales increased 11.5%Reported operating income margin of 19.7%Adjusted operating income margin(1) increased 130 bps to 24.7%Reported EPS increased 20.0% to $2.16Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.8 % (0.1) % 12.9 % 0.2 % 12.7 %Orthopaedics and Spine 10.7
Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. "The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers," said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. "We look forward to enabling physicians with the minimally invasive mild® procedure so patients can reclaim their quality of life." The addition of Vertos Me
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition further strengthens Stryker's commitment to neurotechnology through tumor and stroke care. ICH, or bleeding in the brain caused by a ruptured blood vessel, is the deadliest form of stroke, affecting over 3.4 million people annually ar
Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stry
SAN JOSE, California, USA, July 31, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's commitment to advancing surgical solutions in breast cancer care. The MOLLI 2 localization system is designed for ease of use and reliability to support a more efficient surgical workflow. The MOLLI Mar
Portage, Michigan, July 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2024: Second Quarter Results Reported net sales increased 8.5% to $5.4 billionOrganic net sales increased 9.0%Reported operating income margin of 19.4%Adjusted operating income margin(1) increased 30 bps to 24.6%Reported EPS increased 10.9% to $2.14Adjusted EPS(1) increased 10.6% to $2.81 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 9.0 % (0.8) % 9.8 % 0.1 % 9.7
Portage, Michigan, May 09, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable July 31, 2024 to shareholders of record at the close of business on June 28, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryk
Portage, Michigan, April 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results Reported net sales increased 9.7% to $5.2 billionOrganic net sales increased 10.0%Reported operating income margin of 18.5%Adjusted operating income margin(1) increased 80 bps to 21.9%Reported EPS increased 33.1% to $2.05Adjusted EPS(1) increased 16.8% to $2.50 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 11.5 % (0.5) % 12.0 % 0.4 % 11.6
Portage, Michigan, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable April 30, 2024 to shareholders of record at the close of business on March 29, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker im
Portage, Michigan, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2023: Fourth Quarter Results Reported net sales increased 11.8% to $5.8 billionOrganic net sales increased 11.4%Reported operating income margin of 21.6%Adjusted operating income margin(1) increased 60 bps to 27.2%Reported EPS increased 102.7% to $2.98Adjusted EPS(1) increased 15.3% to $3.46 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.3 % 0.3 % 12.0 % 0.2 %
10-Q - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
CERT - STRYKER CORP (0000310764) (Filer)
8-A12B - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
424B5 - STRYKER CORP (0000310764) (Filer)
424B5 - STRYKER CORP (0000310764) (Filer)
FWP - STRYKER CORP (0000310764) (Subject)
FWP - STRYKER CORP (0000310764) (Subject)
424B5 - STRYKER CORP (0000310764) (Filer)
FLOWER MOUND, Texas, USA, Nov. 19, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons to focus on delivering the highest standard of care. In today's operating rooms, where precision and accuracy are critical, even the smallest challenges may impact surgical outcomes – factors which may impede a surgeon's ability to see clearly and work efficiently. "The Oculan Lighting Platform was developed in respo
PORTAGE, Mich., USA, Nov. 14, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals. Maternal mortality has been rising in the U.S. for decades,1 with approximately 50,000 c
Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billionOrganic net sales increased 11.5%Reported operating income margin of 19.7%Adjusted operating income margin(1) increased 130 bps to 24.7%Reported EPS increased 20.0% to $2.16Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.8 % (0.1) % 12.9 % 0.2 % 12.7 %Orthopaedics and Spine 10.7
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
PONTE VEDRA, Fla., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. (collectively, "Stryker") (NYSE:SYK), alleging infringement of 9 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies and unfair competition. The suit was filed in the United States District Court for the District of New Jersey, a
Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report its third quarter 2024 financial results on Tuesday, October 29, 2024. A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the quarter ended September 30, 2024. Stryker will host a webcast at 4:30pm ET on Tuesday, October 29, to discuss results for the third quarter. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours after the live call ends. About Stryker Stryk
Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. "The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers," said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. "We look forward to enabling physicians with the minimally invasive mild® procedure so patients can reclaim their quality of life." The addition of Vertos Me
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition further strengthens Stryker's commitment to neurotechnology through tumor and stroke care. ICH, or bleeding in the brain caused by a ruptured blood vessel, is the deadliest form of stroke, affecting over 3.4 million people annually ar
Portage, Michigan, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), announced that it has completed the previously announced acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. "We welcome the care.ai team to Stryker and look forward to working together to accelerate our digital vision to provide customers with real-time, smart and connected decision-making tools that can enhance the lives of caregivers and their patients," stated Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. The acquisition will strengthen Stryker's growing healthcare IT offer
Details How Independent Third Parties and the Evidence in Legal Proceedings Have Consistently Refuted Masimo's "Defensive Rhetoric" and How Company's Attacks on Politan Continue to "Crumble Under Basic Scrutiny" Shareholders Can Vote for Politan's Independent Nominees, Darlene Solomon and William Jellison, on the WHITE Card and Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today issued an open letter to shareholders in advance of the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting"), set for September 19. Th
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
Needham upgraded Stryker from Hold to Buy and set a new price target of $392.00
Canaccord Genuity upgraded Stryker from Hold to Buy and set a new price target of $360.00 from $315.00 previously
ROTH MKM initiated coverage of Stryker with a rating of Buy and set a new price target of $345.00
BofA Securities upgraded Stryker from Neutral to Buy and set a new price target of $315.00 from $310.00 previously
UBS initiated coverage of Stryker with a rating of Neutral and set a new price target of $287.00
KeyBanc Capital Markets initiated coverage of Stryker with a rating of Sector Weight
RBC Capital Mkts upgraded Stryker from Sector Perform to Outperform and set a new price target of $284.00 from $240.00 previously
Canaccord Genuity downgraded Stryker from Buy to Hold and set a new price target of $220.00 from $225.00 previously
Stryker's (NYSE:SYK) short percent of float has risen 7.55% since its last report. The company recently reported that it has 4.11 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.41 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
Stryker (NYSE:SYK) has outperformed the market over the past 10 years by 4.7% on an annualized basis producing an average annual return of 15.6%. Currently, Stryker has a market capitalization of $130.48 billion. Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $4,267.32 today based on a price of $342.50 for SYK at the time of writing. Stryker's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed
Morgan Stanley analyst Drew Ranieri maintains Stryker (NYSE:SYK) with a Equal-Weight and raises the price target from $345 to $350.
BTIG analyst Ryan Zimmerman maintains Stryker (NYSE:SYK) with a Buy and raises the price target from $369 to $372.
Stryker (NYSE:SYK) has outperformed the market over the past 10 years by 4.1% on an annualized basis producing an average annual return of 15.02%. Currently, Stryker has a market capitalization of $127.79 billion. Buying $100 In SYK: If an investor had bought $100 of SYK stock 10 years ago, it would be worth $401.97 today based on a price of $335.44 for SYK at the time of writing. Stryker's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
Ratings for Stryker (NYSE:SYK) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 1 0 0 3M Ago 4 6 1 0 0 Analysts have set 12-month price targets for Stryker, revealing an average target of $378.57, a high estimate of $405.00, and a low estimate of $351.00. This current average has increased by 5.25% from the previous
Evercore ISI Group analyst Vijay Kumar maintains Stryker (NYSE:SYK) with a Outperform and lowers the price target from $370 to $365.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BEARISH 07/19/24 $28.00 $74.9K 29.5K 5.7K ZTS CALL SWEEP BEARISH 07/19/24 $170.00 $39.
Stryker (NYSE:SYK) has outperformed the market over the past 10 years by 4.28% on an annualized basis producing an average annual return of 15.2%. Currently, Stryker has a market capitalization of $132.83 billion. Buying $100 In SYK: If an investor had bought $100 of SYK stock 10 years ago, it would be worth $408.95 today based on a price of $348.67 for SYK at the time of writing. Stryker's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
Artelon is a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. The acquisition will strengthen Stryker's offerings in the soft tissue fixation segment and highlights Stryker's commitment to providing differentiated solutions for ligament and tendon reconstruction.
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
EMERYVILLE, Calif., Sept. 12, 2024 /PRNewswire/ -- Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, today announced the appointment of Brent D. Lang, former Chairman and CEO of Vocera Communications, to its Board of Directors. Lang brings over three decades of healthcare and technology experience, having led Vocera through rapid growth, a successful IPO, and its $3 billion acquisition by Stryker (NYSE:SYK). His strategic vision and proven leadership will guide Eko as it continues to innovate and expand its platform
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
FREMONT, Calif., Sept. 1, 2021 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the appointment of Stuart F. Simpson as its president and chief executive officer. Mr. Simpson's decades of experience in the medical device industry, particularly his deep understanding of the orthopedics industry and orthopedic surgical robots, makes him the ideal person to lead THINK Surgical. Mr. Simpson had a successful 24-year career at Stryker Corporation (NYSE:SYK) holding roles of increasing responsibility in Europe, Asia Paci
As the pioneer of the first FDA-approved continuous glucose monitor, Dr. Mastrototaro will be integral in advancing the development and regulatory process of the Company's glucose and blood pressure monitoring technology PLEASANTON, CA / ACCESSWIRE / March 25, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021. Movano's founder and current CEO, Michael Leabman, will become the Company's CTO and will remain on the Company's Board of Directors. Dr. M
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors
Kalamazoo, Michigan, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.63 per share payable January 29, 2021 to shareholders of record at the close of business on December 31, 2020, representing an increase of 9.6% versus the prior year and previous quarter. “We continue to drive solid financial results in a challenging environment, and consistent with our stated capital allocation philosophy, are raising our dividend 9.6%," said Kevin Lobo, Chairman and Chief Executive Officer. Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healt